Immuneering presents atebimetinib Phase 3 pancreatic cancer trial plans, targets mid-2028 topline data
IMRX•Immuneering is enrolling a Phase 3 trial of atebimetinib with modified chemotherapy for first-line pancreatic cancer, with topline results expected in mid-2028. Phase 2 data showed median overall survival of 17.3 months.
1. Pancreatic cancer trial
Immuneering is enrolling a Phase 3 trial of atebimetinib with modified chemotherapy in first-line pancreatic cancer and expects topline results in mid-2028. Phase 2 data presented at ASCO showed median overall survival of 17.3 months; an update is expected in the first half of 2027.
2. Other pipeline programs
A collaboration with Astellas targets CLDN18.2-positive pancreatic cancer using atebimetinib combinations, including chemotherapy-free regimens. Immuneering also has Phase 2 lung cancer combinations with Regeneron and Eli Lilly.
